↓ Skip to main content

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer

Overview of attention for article published in Frontiers in oncology, September 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
3 X users

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
2 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
Published in
Frontiers in oncology, September 2022
DOI 10.3389/fonc.2022.852885
Pubmed ID
Authors

Baozhen Ma, Yu Zhou, Yiman Shang, Yong Zhang, Benling Xu, Xiaomin Fu, Jindong Guo, Yonghao Yang, Fang Zhang, Mengyuan Zhou, Hao Huang, Fanghui Li, Hongwei Lin, Lingdi Zhao, Zibing Wang, Quanli Gao

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 2 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 2 100%

Demographic breakdown

Readers by professional status Count As %
Lecturer 1 50%
Student > Master 1 50%
Readers by discipline Count As %
Environmental Science 1 50%
Immunology and Microbiology 1 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2022.
All research outputs
#17,881,371
of 26,178,577 outputs
Outputs from Frontiers in oncology
#8,278
of 22,922 outputs
Outputs of similar age
#256,870
of 436,552 outputs
Outputs of similar age from Frontiers in oncology
#667
of 1,802 outputs
Altmetric has tracked 26,178,577 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,922 research outputs from this source. They receive a mean Attention Score of 3.1. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 436,552 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,802 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.